A woman who is at least the fourth generation of her family, who faces a “cruel” brain disorder, who leaves people trapped in her body, hoping that a drug test gives hope to future patients Can

The 58 -year -old Samantha is neuroferitinopathy in Danisson, a rare disease that mainly affects a small number of families with roots in Kambria.

She is participating in a test to see if the existing drug, Dephripone, can remove iron formation in the brain that causes the disease.

In 2001, the status discovered by Medix in Newcastle, usually as a result of patients lose the ability to talk or move forward, is fully discovered about the world around them.

Scientists believe that there may be about 100 people with neuropharytinopathy worldwide, but as long as they are diagnosed, their children can also have children carrying genes.

Those who discovered the condition and named them and said that it was often described as Parkinson’s or Huntington’s disease before 2001.

One of the scientists of Newcastle, Professor Patrick Chinneri, had moved forward with the influence of this condition on patients and their families, he had become firm to find a treatment or, better, still, a cure.

He is leading the define Test at Cambridge University And described the situation as “cruel” because it left the patients “trapped”, unable to communicate with the people around them.

The whole family may be affected at a time, including Four sisters in cumbria Whose story was shown by the BBC ahead of the Cambridge trial last year.

Bradford’s Mrs. Denisson was the first person to scan her brain to study and recently returned to Cambridge for another MRI.

She now moves and barely talks and said that the condition had left the mark of destruction for her family.

“My brother has this, my father had this, his mother had it and so his mother,” he said.

The Cambridge Trial, approved by the Medicine and Healthcare Products Regulatory Agency, is being supported by £ 750,000 from LifeARC Rare Diseases Translational Challenge.

When successful, Professor Chinneri said that doctors may be able to give different to people before developing symptoms.

For patients, this means “a possible treatment” and can pave the way for treating other conditions associated with iron formation in the brain.

“If we can show in the situation that reducing iron prevents nerve cells from being damaged, then there is no major jump to suggest that a similar approach can be helpful in Parkinson’s disease or Alzheimer’s disease,” Prof. Chinneri said.

Testing is a double-blind study, so no one knows who is on the drug and who is taking placebo, researchers have monitored the change in iron levels in all participants.

Cambridge University is still recruiting testing subjects and if Avoid – As an existing approved drug – works, it is expected that doctors will be able to determine it quickly.

Now with his own speech, Samantha Danison said that his great desire was for future generations.

He said: “If they can have a disease in its tracks, it will be absolutely surprising.”

Follow BBC North East X, Facebook, Next door And Instagram And on BBC Cumbria X, Facebook, Next door And InstagramSend your story ideas Here,